This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Biotech Stock Roundup: BMY, TSVT Down on Setback, TRDA, MOR Offer Updates
by Zacks Equity Research
Regulatory setback for Bristol Myers (BMY) and other updates are in focus in the biotech sector.
MORPositive Net Change TRDANegative Net Change
biotechnology biotechs pharmaceuticals
Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug
by Zacks Equity Research
Mesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate, Ryoncil, for acute graft versus host disease. The stock rises 11%.
NVSNegative Net Change INCYNegative Net Change LGNDNegative Net Change MESONegative Net Change
biotechnology biotechs medical pharmaceuticals
Civeo (CVEO)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
CVEOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Avita (RCEL) Falls 19% on Lowered 2023 Revenue Guidance
by Zacks Equity Research
Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.
LGNDNegative Net Change AGENNegative Net Change ACADNegative Net Change RCELNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.
GILDNegative Net Change DVAXNegative Net Change LGNDNegative Net Change ACADNegative Net Change CRSPNegative Net Change
biotechnology biotechs
Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson
by Zacks Equity Research
Can-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.
LGNDNegative Net Change AGENNegative Net Change CANFNegative Net Change ACADNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers (BMY), TSVT Cell Therapy Abecma Faces Setback
by Zacks Equity Research
Bristol Myers Squibb (BMY) and 2seventy bio, Inc.'s efforts to seek approval for the label expansion of Abecma for earlier lines of treatment face a roadblock.
BMYNegative Net Change BAYRYNegative Net Change
biotechnology pharmaceuticals
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics
by Zacks Equity Research
Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.
GILDNegative Net Change SRPTNegative Net Change EXASNegative Net Change BGNEPositive Net Change LEGNNegative Net Change
biotechnology
Anavex (AVXL) Up 12% on Regulatory Update for Alzheimer's Drug
by Zacks Equity Research
Anavex (AVXL) announces an encouraging regulatory update for its investigational candidate, blarcamesine, in the treatment of Alzheimer's disease. The stock rises 12%.
LGNDNegative Net Change AGENNegative Net Change ACADNegative Net Change AVXLNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bayer (BAYRY) Stops Heart Drug Study Due to Lack of Efficacy
by Zacks Equity Research
Bayer's (BAYRY) phase III cardiovascular drug study is stopped due to low efficacy compared with Eliquis. The company suffers another setback in Roundup Litigation.
DVAXNegative Net Change BAYRYNegative Net Change LGNDNegative Net Change
biotechnology pharmaceuticals
After Golden Cross, Robert Half (RHI)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
RHINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy First Business Financial Services (FBIZ) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
FBIZNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why
by Zacks Equity Research
Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.
LGNDNegative Net Change AGENNegative Net Change ACADNegative Net Change RPTXNegative Net Change
biotechnology biotechs gene-editing medical oncology-screening pharmaceuticals
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.
GILDNegative Net Change SRPTNegative Net Change EXASNegative Net Change BGNEPositive Net Change LEGNNegative Net Change
biotechnology
Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market
by Zacks Equity Research
Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.
BIIBNegative Net Change RHHBYNegative Net Change BMYNegative Net Change PRTANegative Net Change
biotechnology biotechs pharmaceuticals
Exelixis (EXEL) Gains 30% YTD on Cabometyx, Pipeline Progress
by Zacks Equity Research
Exelixis (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.
BMYNegative Net Change TEVANegative Net Change EXELNegative Net Change
biotechnology biotechs pharmaceuticals
Princeton Bancorp (BPRN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
BPRNNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Chemed (CHE) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
CHENegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Deutsche Bank (DB)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
DBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Strategic Education (STRA) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
STRANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
by Zacks Equity Research
Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.
LGNDNegative Net Change ACADNegative Net Change ANIXNegative Net Change DRMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia
by Zacks Equity Research
Ardelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%.
LGNDNegative Net Change ACADNegative Net Change ARDXNegative Net Change ANIXNegative Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics
by Zacks Equity Research
Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.
BMYNegative Net Change VRTXNegative Net Change CRSPNegative Net Change SLDBNegative Net Change ACLXNegative Net Change
biotechnology
Bristol Myers (BMY) Receives FDA Approval for NSCLC Drug
by Zacks Equity Research
Bristol Myers' (BMY) repotrectinib, a tyrosine kinase inhibitor (???TKI???) targeting ROS1 oncogenic fusions, gets FDA???s approval for NSCLC.
BMYNegative Net Change DVAXNegative Net Change MRKNegative Net Change LGNDNegative Net Change
biotechnology pharmaceuticals
Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod
by Zacks Equity Research
Bristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector.
BMYNegative Net Change VRTXNegative Net Change CRSPNegative Net Change SLDBNegative Net Change ACLXNegative Net Change
biotechnology